Progressive multifocal leukoencephalopathy in two psoriasis patients treated with efalizumab

Journal of Drugs in Dermatology

Volumn 9, Issue 8, 2010, Pages 1005-1009

  Gadzia, Joseph ^a   Turner, James ^b  

^a Kansas Medical Clinic   (United States)

^b Mid South Dermatology and Skin Cancer Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPHENHYDRAMINE; EFALIZUMAB; ESCITALOPRAM; LORAZEPAM; MORPHINE; OLANZAPINE; PRAMOCAINE; PRAVASTATIN; SIMVASTATIN; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

AGED; AGITATION; ARTICLE; BEHAVIOR CHANGE; BRAIN INFARCTION; CASE REPORT; CONFUSION; CORONARY ARTERY DISEASE; DEPRESSION; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; HEMIPARESIS; HUMAN; HYPERLIPIDEMIA; MALE; MOTOR CONTROL; NUCLEAR MAGNETIC RESONANCE IMAGING; PALLIATIVE THERAPY; PARESTHESIA; PATIENT ASSESSMENT; PERSONALITY; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; PSORIASIS; SIDE EFFECT; SKIN TINGLING; SLURRED SPEECH; SYMPTOM; THROMBOEMBOLISM; TREATMENT DURATION; VERTIGO; CHRONIC DISEASE; ISOLATION AND PURIFICATION; JC VIRUS; VIROLOGY;

AGED; ANTIBODIES, MONOCLONAL; CHRONIC DISEASE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JC VIRUS; LEUKOENCEPHALOPATHY, PROGRESSIVE MULTIFOCAL; MALE; PSORIASIS;

EID: 77955902380     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Aksamit AJ. Review of progressive multifocal leukoencephalopathy and natalizumab. Neurologist. 2006;12:293-298. (Pubitemid 44813665)
2. Berger JR. Natalizumab and progressive multifocal leucoencephalopathy. Ann Rheum Dis. 2006;65(Suppl 3):iii48-iii53.
3. Garcia-Suarez J, De Miguel D, Krsnik I, et al. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: Impact of novel therapies. Am J Hematol. 2005;80:271-281. (Pubitemid 41746174)
4. Koralnik IJ, Schellingerhout D, Frosch MP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 14-2004. A 66-year-old man with progressive neurologic deficits. N Engl J Med. 2004;350:1882-1893.
5. Selik RM, Karon JM, Ward JW. Effect of the human immunodeficiency virus epidemic on mortality from opportunistic infections in the United States in 1993. J Infect Dis. 1997;176:632-636. (Pubitemid 27360526)
6. Padgett BL, Walker DL. Prevalence of antibodies in human sera against JC virus, an isolate from a case of progressive multifocal leukoencephalopathy. J Infect Dis. 1973;127:467-470.
7. Berger JR, Concha M. Progressive multifocal leukoencephalopathy: The evolution of a disease once considered rare. J Neurovirol. 1995;1:5-18.
8. Berger JR, Kaszovitz B, Post MJ, Dickinson G. Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases. Ann Intern Med. 1987;107:78-87. (Pubitemid 17098643)
9. Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood. 2002;99:1486-1488. (Pubitemid 34547110)
10. Matteucci P, Magni M, Di Nicola M, et al. Leukoencephalopathy and papovavirus infection after treatment with chemotherapy and anti-CD20 monoclonal antibody. Blood. 2002;100:1104-1105. (Pubitemid 34832655)
11. Steurer M, Clausen J, Gotwald T, et al. Progressive multifocal leukoencephalopathy after allogeneic stem cell transplantation and posttransplantation rituximab. Transplantation. 2003;76:435-436. (Pubitemid 36928014)
12. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113:4834-4840.
13. Jullien D, Prinz JC, Langley RGB, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva™): Mechanisms of action. Dermatology. 2004;208:297-306. (Pubitemid 38736650)
14. Mortensen DL, Walicke PA, Wang X, et al. Pharmacokinetics and pharmacodynamics of multiple weekly subcutaneous efalizumab doses in patients with plaque psoriasis. J Clin Pharmacol. 2005;45:286-298. (Pubitemid 40490426)
15. Genentech. Important drug warning regarding RAPTIVA® (efalizumab) [health care provider letter]. South San Francisco, CA: Genentech, Inc.; 10 February 2009. Available at www.gene.com/gene/products/information/pdf/raptiva- dhcp-pml3.pdf. Accessed May 21, 2009.
16. Wendt M, Wohlrab J, Zierz S, Deschauer M. Efalizumab-induced isolated cerebral lupus-like syndrome. Neurology. 2009;72:96-97.
17. Krueger JG, Ochs HD, Patel P, et al. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: Results of a randomized, single blind study. J Invest Dermatol. 2008;128:2615-2624.
18. Stuve O, Marra CM, Bar-Or A, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol. 2006;63:1383-1387. (Pubitemid 44547548)
19. Stuve O, Marra CM, Jerome KR, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol. 2006;59:743-747. (Pubitemid 43673151)
20. U.S. Food and Drug Administration. Natalizumab (marketed as Tysabri) information. FDA alert [8/2008]. Available at www.fda.gov/cder/drug/infopage/ natalizumab. Accessed May 21, 2009.
21. Kiewe P, Seyfert S, Korper S, et al. Progressive multifocal leukoencephalopathy with detection of JC virus in a patient with chronic lymphocytic leukemia parallel to onset of fludarabine therapy. Leuk Lymphoma. 2003;44:1815-1818. (Pubitemid 37221060)
22. Montoto S, Moreno C, Domingo-Domenech E, et al. High clinical and molecular response rates with fludarabine, cyclophosphamide and mitoxantrone in previously untreated patients with advanced stage follicular lymphoma. Haematologica. 2008;93:207-214. (Pubitemid 351409330)
23. Adkins JC, Peters DH, Markham A. Fludarabine. An update of its pharmacology and use in the treatment of haematological malignancies. Drugs. 1997;53:1005-1037. (Pubitemid 27254575)
24. Crowder CD, Gyure KA, Drachenberg CB, et al. Successful outcome of progressive multifocal leukoencephalopathy in a renal transplant patient. Am J Transplant. 2005;5:1151-1158. (Pubitemid 40571268)
25. Kharfan-Dabaja MA, Ayala E, Greene J, et al. Two cases of progressive multifocal leukoencephalopathy after allogeneic hematopoietic cell transplantation and a review of the literature. Bone Marrow Transplant. 2007;39:101-107. (Pubitemid 46085228)
26. Martinez AJ, Ahdab-Barmada M. The neuropathology of liver transplantation: Comparison of main complications in children and adults. Mod Pathol. 1993;6:25-32.
27. Shitrit D, Lev N, Bar-Gil-Shitrit A, Kramer MR. Progressive multifocal leukoencephalopathy in transplant recipients. Transpl Int. 2005;17:658-665. (Pubitemid 40558222)
28. Fong IW, Britton CB, Luinstra KE, et al. Diagnostic value of detecting JC virus DNA in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathy. J Clin Microbiol. 1995;33:484-486.
29. Dorries K, Sbiera S, Drews K, et al. Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals. J Neurovirol. 2003;9(suppl 1):81-87. (Pubitemid 36656476)
30. Wei G, Liu CK, Atwood WJ. JC virus binds to primary human glial cells, tonsillar stromal cells, and B-lymphocytes, but not to T lymphocytes. J Neurovirol. 2000;6:127-136. (Pubitemid 30303571)
31. Du Pasquier RA, Kuroda MJ, Zheng Y, et al. A prospective study demonstrates an association between JC virus-specific cytotoxic T lymphocytes and the early control of progressive multifocal leukoencephalopathy. Brain. 2004;127(Part 9):1970-1978. (Pubitemid 39150256)
32. Wuthrich C, Kesari S, Kim WK, et al. Characterization of lymphocytic infiltrates in progressive multifocal leukoencephalopathy: Colocalization of CD8(+) T cells with JCV-infected glial cells. J Neurovirol. 2006;12:116-128. (Pubitemid 44590938)
33. Dietrich JB. The adhesion molecule ICAM-1 and its regulation in relation with the blood-brain barrier. J Neuroimmunol. 2002;128:58-68.
34. Greenwood J, Etienne-Manneville S, Adamson P, Couraud PO. Lymphocyte migration into the central nervous system: implication of ICAM-1 signalling at the blood-brain barrier. Vascul Pharmacol. 2002;38:315-322. (Pubitemid 36398253)